Obsidian Therapeutics Inc. raised $49.5m in Series A venture capital to develop its technology for inserting a synthetic tag into chimeric antigen receptor T cell (CAR-T) therapies so that the they can be activated or deactivated as needed for efficacy or safety.
That's just one of three initial uses for Obsidian's technology that CEO Michael Gilman described in an interview with Scrip on Dec. 6 when the company announced its Series A round. The start-up – the second venture that Gilman's launched this year – is based on technology that the entrepreneur worked on at the start of his biopharmaceutical career, but was shelved before making it into the mainstream
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?